DEVELOPMENT OF THERAPEUTIC PRODUCTS FOR COVID-19

NIH Pandemic-Era Grants

Pandemic Era Grants

2020

↗ Live URL (may be dead)

Document text

Principal Investigator: JEFFREY  GLENN
Organization: STANFORD UNIVERSITY
Fiscal Year: 2020
Award: $14,260,074
Funding agency: National Institute of Allergy and Infectious Diseases

To support the advanced development of a promising candidate therapeutic for NIAID Category A, B, and C Priority Pathogens or emerging infectious diseases. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.

Terms: <2019 novel coronavirus><2019-nCoV><Advanced Development><COVID-19><COVID19><Categories><Chemistry><Clinical><Development><Development and Research><Emerging Communicable Diseases><Emerging Infectious Diseases><NIAID><National Institute of Allergy and Infectious Disease><Pathway interactions><R & D><R&D><SARS-CoV-2><SARS-CoV2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Safety><Severe acute respiratory syndrome coronavirus 2><Wuhan coronavirus><corona virus disease 2019><coronavirus disease 2019><developmental><pathway><pre-clinical><preclinical><priority pathogen><product development><research and development><therapeutic agent development><therapeutic candidate><therapeutic development>